ASCO 2026 | Predictors of toxicity and tolerability with lifileucel in advanced melanoma
Alexandra Haugh
• 30 May 2026
Alexandra Haugh, MD, MPH, of Massachusetts General Hospital Cancer Center, discusses patient characteristics associated with tolerability and toxicity risk following lifileucel treatment in pretreated advanced melanoma. Dr Haugh highlights the impact of age, disease burden, baseline bone marrow reserve, and bridging therapy on treatment-related toxicities and blood count recovery. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
